Monday, December 14, 1998
Biotechnology drug discovery efforts often focus on potency
- the affinity that a compound has against a particular target. While such affinity
is useful from a biological standpoint, it is not the only factor in determining
whether a compound succeeds in subsequent development.
Indeed, Robert Lipper, vice president of biopharmaceutics research
and development at Bristol-Myers Squibb Co. (Princeton, N.J.), argues that biopharmaceutical
parameters relating to formulation and delivery must be taken into account at
an early stage to avoid selecting sub-optimal compounds for development, which
can lead to costly delays.